Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1960375 | 0.82 | KDM4E (0.46) | ALDH1A1TSHRKDM4EUSP2LMNA | |
| SCHEMBL6278755 | 0.76 | ALDH1A1 (0.50) | ALDH1A1TSHRKDM4EUSP2SMN1; SMN2 | |
| SCHEMBL3589537 | 0.76 | TAAR1 (0.47) | ALDH1A1TSHRKDM4EUSP2LMNA | |
| SCHEMBL5659205 | 0.75 | PTGS2 (0.43) | FFAR1CYP19A1 | |
| SCHEMBL2996214 | 0.75 | TAAR1 (0.46) | NR3C1ALDH1A1TSHRKDM4EUSP2 | |
| SCHEMBL4852971 | 0.75 | TAAR1 (0.46) | ALDH1A1TSHRKDM4EUSP2LMNA | |
| SCHEMBL3128402 | 0.75 | TAAR1 (0.47) | ALDH1A1HTTTSHRKDM4EUSP2 | |
| SCHEMBL17372880 | 0.75 | TAAR1 (0.46) | ALDH1A1TSHRKDM4EUSP2LMNA | |
| SCHEMBL2061401 | 0.75 | KDM4E (0.39) | ALDH1A1TSHRKDM4EUSP2LMNA | |
| SCHEMBL7155961 | 0.75 | ALDH1A1 (0.39) | ALDH1A1TSHRKDM4EUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227296-B2 | Bis(sulfonamide) derivatives and their use as mPGES inhibitors | Arcturum Real Estate AB (SE) | 2019-03-12 | — | — | US | disclosed |
| US-10227296-B2 | Bis(sulfonamide) derivatives and their use as mPGES inhibitors | Arcturum Real Estate AB (SE) | 2019-03-12 | — | — | US | disclosed |
| US-20180002278-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | ACTURUM REAL ESTATE AB (SE) | 2018-01-04 | — | — | US | disclosed |
| US-20180002278-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | ACTURUM REAL ESTATE AB (SE) | 2018-01-04 | — | — | US | disclosed |
| EP-3224241-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | Acturum Real Estate AB (SE) | 2017-10-04 | — | — | EP | disclosed |
| CN-107001251-A | Double (sulfonamide) derivatives and its purposes as MPGES inhibitor | 埃克杜鲁姆房地产有限公司 | 2017-08-01 | — | — | CN | disclosed |
| WO-2016085391-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | Acturum Life Science AB (SE) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016085391-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | Acturum Life Science AB (SE) | 2016-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227296-B2 | Bis(sulfonamide) derivatives and their use as mPGES inhibitors | PTGES, PTGS1, PTGES2 | NR3C1 1632/4885ALDH1A1 394/4885HTT 4380/4885 |
| US-20180002278-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | PTGES, PTGS1, PTGES2 | NR3C1 1632/4885ALDH1A1 394/4885HTT 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.